Journal
HEPATOLOGY INTERNATIONAL
Volume 11, Issue 3, Pages 255-267Publisher
SPRINGER
DOI: 10.1007/s12072-017-9790-5
Keywords
Alcoholic hepatitis; Corticosteroids; Granulocyte-colony stimulating factor; Molecular targeted therapy; Liver transplantation
Categories
Ask authors/readers for more resources
Severe alcoholic hepatitis (SAH) is defined by modified Maddrey discriminant function 32 or Model for End-Stage Liver Disease (MELD) > 21 and/or hepatic encephalopathy. It has a 3-month mortality rate 30-70 %. Patients with severe alcoholic hepatitis need combined, i.e., static (MELD score) and dynamic (Lille's score), prognostication. Systemic inflammation and poor regeneration are hallmarks of SAH, rather than intrahepatic inflammation. SAH is characterized by dysregulated and uncontrolled systemic inflammatory response followed by weak compensatory antiinflammatory response that leads to increased susceptibility to infection and multiple organ failure. Massive necrosis of hepatocytes exceeds the proliferative capacity of hepatocytes. Liver progenitor cells proliferate to form narrow ductules which radiate out into the damaged liver parenchyma. Corticosteroids have been the standard-of-care therapy, albeit controversial. However, the recent Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial revealed that prednisolone was not associated with a significant reduction in 28-day mortality, with no improvement in outcomes at 90 days or 1 year. A paradigm shift from antiinflammatory therapy such as corticosteroids to liver regeneration treatment, e.g., granulocyte-colony stimulating factor, molecular targeted treatments, and fecal microbiota transplantation, for severe alcoholic hepatitis is taking place. Liver transplantation should be offered to select patients with severe alcoholic hepatitis who are nonresponsive to medical treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available